Correlation of [ 68 Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients.

Emilio Francesco GiuntaPaola CaroliEmanuela ScarpiAmelia AltavillaVirginia RossettiIrene MariniMonica CelliChiara CasadeiCristian LolliGiuseppe SchepisiSara BleveNicole BrighiMaria Concetta CursanoGiovanni PaganelliFederica MatteucciUgo De Giorgi

Published in: European journal of nuclear medicine and molecular imaging (2024)

Ga]Ga-PSMA PET could be a useful imaging tool for monitoring response to enzalutamide in mCRPC patients, being more informative than PSA in this setting, and possibly better guiding clinicians in therapeutic decisions.

Keyphrases

small cell lung cancer
pet ct
prostate cancer
positron emission tomography
end stage renal disease
newly diagnosed
squamous cell carcinoma
high resolution
palliative care
computed tomography
radical prostatectomy